PXS Share Price

Open 0.27 Change Price %
High 0.27 1 Day 0.00 0.00
Low 0.26 1 Week 0.01 3.85
Close 0.27 1 Month 0.02 8.00
Volume 327391 1 Year -0.03 -10.00
52 Week High 0.31
52 Week Low 0.23
PXS Important Levels
Resistance 2 0.28
Resistance 1 0.28
Pivot 0.27
Support 1 0.26
Support 2 0.26
ASX Australia Most Active Stocks
LYC 0.15 7.14%
TLS 3.90 0.78%
TLS 3.90 0.78%
TLS 3.90 0.78%
PCL 0.00 0.00%
PCL 0.00 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
VKA 0.02 100.00%
CAV 0.02 100.00%
CAV 0.02 100.00%
GMD 0.02 100.00%
GMD 0.02 100.00%
RDS 0.02 100.00%
RDS 0.02 100.00%
RDS 0.02 100.00%
AZZ 0.50 78.57%
More..
ASX Australia Top Losers Stocks
NME 0.00 -100.00%
NME 0.00 -100.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
AZS 0.01 -50.00%
AZS 0.01 -50.00%
More..

Pharmaxis Ltd (ASX: PXS)

PXS Technical Analysis 3
As on 18th Aug 2017 PXS Share Price closed @ 0.27 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.27 & Buy for SHORT-TERM with Stoploss of 0.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
PXS Target for August
1st Target up-side 0.27
2nd Target up-side 0.28
3rd Target up-side 0.29
1st Target down-side 0.25
2nd Target down-side 0.24
3rd Target down-side 0.23
PXS Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.pharmaxis.com.au
PXS Address
PXS
20 Rodborough Road
Frenchs Forest, NSW 2086
Australia
Phone: 61 2 9454 7200
Fax: 61 2 9451 3622
PXS Latest News
Pharmaxis Ltd (ASX:PXS): A Deeper Look At CEO Compensation   Simply Wall St   - 14th Aug 17
Pharmaxis enters new quarter positioned for growth   Proactive Investors Australia   - 28th Jul 17
Pharmaxis Ltd   irasia.com (press release)   - 14th Jun 17
PHARMAXIS ANNOUNCES RESULTS OF PIVOTAL BRONCHITOL CYSTIC FIBROSIS CLINICAL ...   irasia.com (press release)   - 13th Jun 17
Pharmaxis meets primary endpoint of Phase 3 trial of Bronchitol®   Proactive Investors Australia   - 13th Jun 17
Pharmaxis approaching three key potential share price drivers   Proactive Investors Australia   - 19th Apr 17
Pharmaxis Ltd in research collaboration with prestigious institute   Proactive Investors Australia   - 15th Nov 16
Pharmaxis Ltd gets approval to sell Bronchitol® in largest market yet, Russia   Proactive Investors Australia   - 27th Sep 16
Pharmaxis shares spike ahead of promising year   Proactive Investors Australia   - 13th Jan 16
Pharmaxis Limited drug trials success builds product confidence   Proactive Investors Australia   - 22nd Sep 15
Interactive Technical Analysis Chart Pharmaxis Ltd ( PXS ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Pharmaxis Ltd
PXS Business Profile
Pharmaxis Ltd, a pharmaceutical company, is engaged in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory diseases in Australia, European Union, Korea, and the United States. The company’s commercial product includes Aridol, a lung function test designed to assist doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. Its principal product in the development comprises Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions, including cystic fibrosis, bronchiectasis, and chronic bronchitis. Bronchitol is approved for the treatment of cystic fibrosis in adults and pediatric patients in Australia and European Union. The company’s early product development pipeline includes orbital dry powder inhaler that delivers drug doses to the lungs; LOXL-2 inhibitors for the treatment of fibrosis; PXS-4728A–novel SSAO/VAP-1 inhibitor for the treatment of chronic lung inflammation; PXS64/25 targeting lung fibrosis; ASM8 targeting severe asthma; and PXS TPI1100 for the treatment candidate for COPD. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.